Legal opinion of the 2023 annual shareholder meeting of Peking Dacheng (Guangzhou) Law Firm.
Announcement of Resolutions of the Shareholders' Meeting for the Fiscal Year 2023
Announcement on voluntary disclosure of results from Phase II clinical trials of inhaled Remdesivir solution
Notice on convening the 2023 Annual General Meeting of Shareholders
2023 Annual General Meeting of Shareholders Meeting Materials
Notice on Response to the 2023 Annual Report Information Disclosure Regulatory Inquiry Letter
Nanxin Pharmaceutical's 2024 “Improve Quality, Increase Efficiency, and Value Rewards” Action Plan
Notice on retirement and resignation of employee representative supervisors and by-election of employee representative supervisors
Announcement on the extension of some of the company's fund-raising investment projects
Guarantor (Guangzhou Nanxin Pharmaceutical Co., Ltd.) financial statements
Guarantor (Hunan Kaibo Biopharmaceutical Co., Ltd.) financial statements
The company's shareholder return plan for the next three years (2024-2026)
Notice on revising the “Articles of Association” and some corporate governance systems
Constitution of Hunan Nanxin Pharmaceutical Co., Ltd. (revised in March 2024)
Board of Directors Rules of Procedure (Revised March 2024)
Notice on requesting the shareholders' meeting to authorize the board of directors to issue shares to specific targets through simple procedures
Guarantor (Guangzhou Nanxin Pharmaceutical Co., Ltd.) financial statements
2023 Internal Control Evaluation Report
2023 Board Audit Committee Performance Report
Announcement on the retirement and departure of the company\'s core technical personnel
No Data